November 18, 2020
REMAP-CAP is a global adaptive platform trial for community-acquired pneumonia that has extended its domains to investigate new treatments specifically for COVID-19 patients in intensive care units and hospital wards.
REMAP-CAP for COVID-19 in Australia is supported by APPRISE and additional National Health and Medical Research Council (NHMRC) funding, and the trial has already resulted in a paper on the effect of hydrocortisone on mortality and organ support in patients with severe COVID-19.
To explain how the clinical trial platform works, REMAP-CAP has launched its first in a series of videos. The video shows the unique, smart, and easy-to-handle design of this trial. As an adaptive platform, REMAP-CAP is designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment.